Literature DB >> 25714660

Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis.

Cansu Yıldırım1, Sylvia Nieuwenhuis1,2, Paul F Teunissen2, Anton J G Horrevoets1, Niels van Royen2, Tineke C T M van der Pouw Kraan1.   

Abstract

In this review we discuss the current literature on the effects of type I interferons (IFN) and their downstream effectors on vascular growth in experimental models in vitro and in vivo. In addition to its well-documented role in angiogenesis, that is, the growth of new capillaries from existing vessels, we will also describe emerging evidence and mechanisms by which type I IFN may inhibit arteriogenesis, that is, the expansive remodeling of existing collateral arteries. Crucial in both processes is the common role of circulating monocytes, which are known to act as pivotal cellular modulators in revascularization through secreted chemokines, proteases, and growth factors. These secreted molecules, which are all modulated by IFN signaling, act via degradation of the extracellular matrix and by stimulating the proliferation of vascular smooth muscle cells and endothelial cells. Thus, next to the antiviral and immunomodulatory activities of type I IFNs, a potent role of IFN-β as modulator of revascularization is now emerging and may be considered a potential clinical target for the stimulation of angiogenesis and arteriogenesis in ill-perfused tissues.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25714660     DOI: 10.1089/jir.2014.0184

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  6 in total

1.  IFN-β reduces NRP-1 expression on human cord blood monocytes and inhibits VEGF-induced chemotaxis.

Authors:  Anya Nikolai-Yogerst; Paula White; Makio Iwashima
Journal:  Cytokine       Date:  2021-04-13       Impact factor: 3.926

2.  Vascular endothelial effects of collaborative binding to platelet/endothelial cell adhesion molecule-1 (PECAM-1).

Authors:  Raisa Yu Kiseleva; C F Greineder; C H Villa; O A Marcos-Contreras; E D Hood; V V Shuvaev; H M DeLisser; V R Muzykantov
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

Review 3.  An Emerging Role for isomiRs and the microRNA Epitranscriptome in Neovascularization.

Authors:  Reginald V C T van der Kwast; Paul H A Quax; A Yaël Nossent
Journal:  Cells       Date:  2019-12-25       Impact factor: 6.600

Review 4.  STING Agonists as Cancer Therapeutics.

Authors:  Afsaneh Amouzegar; Manoj Chelvanambi; Jessica N Filderman; Walter J Storkus; Jason J Luke
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

5.  Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review.

Authors:  Maxime Dauvergne; David Buob; Cédric Rafat; Marie-Flore Hennino; Mathilde Lemoine; Vincent Audard; Dominique Chauveau; David Ribes; Emilie Cornec-Le Gall; Eric Daugas; Evangéline Pillebout; Vincent Vuiblet; Jean-Jacques Boffa
Journal:  Clin Kidney J       Date:  2021-07-06

6.  Endothelial STING controls T cell transmigration in an IFNI-dependent manner.

Authors:  Marina Anastasiou; Gail A Newton; Kuljeet Kaur; Francisco J Carrillo-Salinas; Sasha A Smolgovsky; Abraham L Bayer; Vladimir Ilyukha; Shruti Sharma; Alexander Poltorak; Francis W Luscinskas; Pilar Alcaide
Journal:  JCI Insight       Date:  2021-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.